Skip to main content
Earle Burgess, MD, Oncology, Charlotte, NC, Atrium Health's Carolinas Medical Center

EarleFBurgessMD

Oncology Charlotte, NC

Genitourinary Oncology, Hematologic Oncology

Genitourinary Oncology Section Chief; Medical Director, Clinical Trials Levine Cancer Institute; Associate Professor of Medicine, Atrium Health

Dr. Burgess is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Burgess' full profile

Already have an account?

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2009
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 2002 - 2004
  • Medical College of Georgia at Augusta University
    Medical College of Georgia at Augusta UniversityClass of 2002
  • Wake Forest University
    Wake Forest UniversityB.S., Magna Cum Laude, 1997

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2024
  • SC State Medical License
    SC State Medical License 2009 - 2015
  • TN State Medical License
    TN State Medical License 2004 - 2009
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow ECCO-AACR-EORTC-ESMO Methods in Clinical Cancer Research, 2014
  • Think Tank Member Bladder Cancer Advocacy Network, 2013
  • Young Investigator Award American Society of Clinical Oncology, 2007

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Individualized Management of Advanced Bladder Cancer: Where Do We Stand?  
    Burgess EF, Urologic Oncology, 1/1/2015
  • Prostate Cancer: What Did We Learn from the 2012 Annual Tumors-What Have We Learned in 35 Years?  
    Riggs S, Burgess EF, Gaston D, Raghavan D, Oncologist, 1/1/2014
  • Prostate Cancer Serum Biomarker Discovery Through Proteomic Analysis of Alpha-2 Macroglobulin Protein Complexes  
    Burgess EF, Ham AL, Tabb DL et al, Proteomics-Clinical Applications, 1/1/2008
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Molecular profiles of small cell bladder and prostate cancer and comparisons with small cell lung cancer.
    Dawson N, Geynisman D, Burgess E, Somer B, Arguello D, Hauke R, Vaena D, Raghavan D, Heath E, J Clin Oncol, 1/1/2018
  • Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor inhibitor, in patients with metastatic or unresectable urothelial carcinoma and FGFR alterati...
    Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, OHagan A, Avadhani A, Zhong B, Stuyc..., Clin Oncol, 1/1/2018
  • Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis o...
    Siefker-Radtke A, Necchi A, Rosenbaum E, Culine S, Burgess E, O'Donnell P, Tagawa S, Zakharia Y, OHagan A, Avadhani A, Zhong B, Santiago-Walker A, Roccia T, Loriot Y, J Clin Oncol, 1/1/2018
  • Join now to see all

Lectures

  • A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73▿
    A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73▿August 4th, 2020
  • A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with mCSPC
    A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with mCSPCJune 4th, 2018
  • ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess
    ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle BurgessNovember 15th, 2018

Professional Memberships

Hospital Affiliations